To get a sense of who is truly in control of Lifecome Biochemistry Co.,Ltd. (SZSE:002868), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are individual insiders with 60% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
Clearly, insiders benefitted the most after the company's market cap rose by CN¥870m last week.
Let's take a closer look to see what the different types of shareholders can tell us about Lifecome BiochemistryLtd.
View our latest analysis for Lifecome BiochemistryLtd
SZSE:002868 Ownership Breakdown November 5th 2022
What Does The Lack Of Institutional Ownership Tell Us About Lifecome BiochemistryLtd?
We don't tend to see institutional investors holding stock of companies that are very risky, thinly traded, or very small. Though we do sometimes see large companies without institutions on the register, it's not particularly common.
There are many reasons why a company might not have any institutions on the share registry. It may be hard for institutions to buy large amounts of shares, if liquidity (the amount of shares traded each day) is low. If the company has not needed to raise capital, institutions might lack the opportunity to build a position. On the other hand, it's always possible that professional investors are avoiding a company because they don't think it's the best place for their money. Lifecome BiochemistryLtd might not have the sort of past performance institutions are looking for, or perhaps they simply have not studied the business closely.
SZSE:002868 Earnings and Revenue Growth November 5th 2022
We note that hedge funds don't have a meaningful investment in Lifecome BiochemistryLtd. The company's largest shareholder is Tan Ping Lai, with ownership of 31%. Meanwhile, the second and third largest shareholders, hold 27% and 7.2%, of the shares outstanding, respectively. Furthermore, CEO Tanping Lai is the owner of 1.0% of the company's shares.
A more detailed study of the shareholder registry showed us that 2 of the top shareholders have a considerable amount of ownership in the company, via their 58% stake.
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.
Insider Ownership Of Lifecome BiochemistryLtd
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
It seems that insiders own more than half the Lifecome Biochemistry Co.,Ltd. stock. This gives them a lot of power. That means they own CN¥2.9b worth of shares in the CN¥4.8b company. That's quite meaningful. Most would be pleased to see the board is investing alongside them. You may wish todiscover (for free) if they have been buying or selling.
General Public Ownership
The general public, who are usually individual investors, hold a 28% stake in Lifecome BiochemistryLtd. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Private Company Ownership
We can see that Private Companies own 12%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 3 warning signs for Lifecome BiochemistryLtd you should know about.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
為了弄清誰真正控制了生命科技生化股份有限公司(深交所:002868),瞭解企業的所有權結構是很重要的。而在這塊蛋糕上分得最大一塊蛋糕的是擁有60%股權的個人內部人士。換句話説,該集團面臨着最大的上行潛力(或下行風險)。
顯然,在上週該公司市值增加8.7億元后,內部人士受益最大。
讓我們仔細看看不同類型的股東能為我們提供什麼關於Lifecome BioChemical Ltd.的信息。
查看我們對Lifecome生物化學有限公司的最新分析
深交所:002868股權明細2022年11月5日
缺乏機構所有權告訴了我們關於Lifecome生化有限公司的什麼?
我們不傾向於看到機構投資者持有風險很高、交易清淡或規模很小的公司的股票。儘管我們有時確實會看到大公司沒有登記在冊的機構,但這種情況並不特別常見。
一家公司可能沒有在股票登記處登記任何機構的原因有很多。如果流動性(每天交易的股票數量)很低,機構可能很難購買大量股票。如果該公司不需要籌集資金,機構可能缺乏建立頭寸的機會。另一方面,專業投資者總是可能會避開一家公司,因為他們認為這不是他們投資的最佳地方。Lifecome BioChemical Ltd可能沒有機構所尋找的那種過去的業績,或者他們只是沒有仔細研究過這項業務。
深交所:002868收益和收入增長2022年11月5日
我們注意到,對衝基金沒有對Lifecome BioChemical Ltd.進行有意義的投資。該公司最大股東為譚平來,持股31%.與此同時,第二大和第三大股東分別持有流通股的27%和7.2%。此外,首席執行官黎定平是該公司1.0%股份的所有者。
對股東登記的更詳細的研究表明,兩個最大的股東通過他們58%的股份在公司擁有相當大的所有權。
雖然研究一家公司的機構持股可以增加你的研究價值,但研究分析師的建議以更深入地瞭解一隻股票的預期表現也是一個很好的做法。我們的信息顯示,分析師沒有對該股進行任何報道,因此它可能鮮為人知。
Lifecome生物化學有限公司的內部人士所有權
不同國家對內部人的定義可能略有不同,但董事會成員總是算數的。公司管理層管理企業,但首席執行官將向董事會負責,即使他或她是董事會成員。
大多數人認為內部人持股是積極的,因為它可以表明董事會與其他股東很好地結盟。然而,在某些情況下,太多的權力集中在這個羣體中。
看來,內部人士持有Lifecome生化股份有限公司一半以上的股份。這給了他們很大的權力。這意味着他們在這家價值48億元的公司中擁有價值29億元的股份。這是很有意義的。大多數人會高興地看到董事會與他們一起投資。您可能希望發現(免費)如果他們一直在買入或賣出。
一般公有制
公眾通常是個人投資者,他們持有Lifecome BioChemical Ltd.28%的股份。這種規模的所有權雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。
私營公司所有權
我們可以看到,私營公司擁有12%的已發行股份。私營公司可能是關聯方。有時,內部人士通過持有一傢俬人公司來對上市公司感興趣,而不是以個人身份。雖然很難得出任何大致的中風結論,但值得注意的是,這是一個值得進一步研究的領域。
接下來的步驟:
我發現看看到底是誰擁有一家公司是非常有趣的。但為了真正獲得洞察力,我們還需要考慮其他信息。例如,考慮一下風險。每家公司都有它們,我們已經發現Lifecome生化有限公司的3個警告標誌你應該知道。
當然了,如果你把目光投向別處,你可能會發現這是一筆很棒的投資。所以讓我們來看看這個免費有趣的公司名單。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。